The Weight-Loss Secret Found in Python Blood: What Is the Newly Discovered pTOS Molecule and How Does It Work?

“Nature-Inspired Biology” and a New Pathway That Could Offer an Alternative to GLP-1 Drugs

Why the Python? The Rationale Behind a Research Strategy

Choosing pythons was a deliberate scientific strategy, rather than a coincidence. To summarize the words of senior author Jonathan Long: if we truly want to understand metabolism, we should go beyond mice and humans and examine the most extreme metabolic examples found in nature . The rationale for using the python is that its physiological fluctuations are so dramatic that molecules barely detectable in other animals become visible in measurable amounts in python blood. The python therefore acts as a “magnifying glass” created by nature.

What is fascinating is how this discovery was made. Leslie Leinwand has studied python cardiac biology for twenty years: after a large meal, the python's heart grows by 25%, its cardiac tissue softens, its pulse doubles, and everything returns to normal within two weeks. Leinwand thought this mechanism could shed light on human heart disease, particularly cardiac fibrosis, the stiffening of heart tissue. While studying post-meal physiological changes, the team noticed the dramatic rise in blood metabolites, unexpectedly turning a cardiac biology study into an obesity discovery.

208 Metabolites, One Standout Molecule

From Tyrosine to Tyramine, and From Tyramine to pTOS

The most striking aspect of pTOS is that, although it appears to be an exotic python molecule, it actually has a familiar origin . pTOS is not a newly synthesized artificial molecule, but a compound the body already produces. Its chemical chain is as follows:

Thus, the starting material for pTOS is tyrosine, an amino acid abundant in everyday protein-rich foods such as chicken, eggs, dairy products and soy. pTOS is not an unknown molecule in humans; although little studied, it was mainly recognized as a compound excreted in urine. The study's main contribution is showing that this “ordinary” molecule may play a role in a gut-brain appetite-suppressing pathway after protein digestion. The study's full title also reflects this: “Python metabolomics uncovers a conserved postprandial metabolite and gut-brain feeding pathway” — meaning “a conserved post-meal metabolite and gut-brain feeding pathway.” “Conserved” is the crucial word: this pathway is not unique to the python but has been conserved throughout evolution in many species, including mammals, and therefore has the potential to function in humans as well.

Why Is It Framed as a “Side-Effect-Free Alternative”?

The reason researchers frame pTOS as a potential alternative to GLP-1 drugs such as semaglutide and tirzepatide is the difference in mechanism. GLP-1/GIP receptor agonists suppress appetite while also slowing gastric emptying, leading to common gastrointestinal side effects such as nausea, vomiting and diarrhea. These were also the most frequent side effects in the SURMOUNT-MAINTAIN study examined in our previous article. pTOS appears to suppress appetite through a different pathway, a gut-brain signaling route, and in mouse experiments it did not show some of the side effects associated with GLP-1 drugs.

Another important distinction is that the researchers reported that pTOS caused weight loss in mice solely through appetite suppression , without changing energy expenditure, metabolic rate, beta-cell proliferation or organ size. The effect of pTOS therefore appears clean and targeted: it produces weight loss simply through “eating less,” without straining other body systems.

The excitement of this discovery does not change the need to avoid exaggerating it. Stanford's accompanying announcement contains a clear warning: to say whether this metabolite found in python blood can smoothly become a human weight-loss drug, it is still far too early. The study currently uses a mouse model; human clinical studies have not been conducted. There is a long road, often ending in failure, between a molecule working in mice and becoming a safe and effective drug in humans, as countless examples in drug-development history show.

In addition, tyramine-based molecules present some known challenges in human pharmacology: tyramine is classically associated with hypertensive crises, the “cheese reaction,” in patients taking a monoamine oxidase inhibitor (MAOI). The sulfated form pTOS may behave differently, but human safety requires detailed investigation. Nevertheless, the fact that the body already produces this molecule may be an advantage for development.

The Obesity-Cancer Axis and New Appetite-Suppressing Pathways

Why does a python metabolite appear on an oncology content platform? The answer lies in the obesity-cancer axisalso discussed in our previous SURMOUNT-MAINTAIN article. The International Agency for Research on Cancer (IARC) identifies obesity as an independent risk factor for at least 13 different cancer types, including postmenopausal breast, colorectal, endometrial, kidney, liver, pancreatic and others. Therefore, every new mechanism providing effective, lasting weight loss indirectly has the potential to become a cancer prevention tool.

One point needs to be emphasized: the relationship between pTOS and cancer prevention is entirely theoretical and indirect. pTOS is not a cancer drug; it is relevant to the prevention side of the obesity-cancer axis only because it is “a potential new tool against obesity.” The real value of this discovery for oncology is not a concrete cancer treatment, but that it provides further evidence of the research potential of metabolic oncology , an expanding field at the intersection of obesity, metabolism and cancer that represents a particularly productive research frontier.

This article is intended as medical news and information and does not provide individual treatment guidance. The discovery of pTOS, para-tyramine-O-sulfate, is currently a basic science finding validated only in an animal model, mice; no human clinical study has been conducted, and pTOS is not available as a drug. A molecule being effective in a mouse model does not mean that it will become a safe and effective treatment in humans. Drug development is a process taking years and often ending in failure. Because tyramine-based molecules have known pharmacological interactions, particularly the risk of hypertensive crisis with MAOI drugs, nobody should try to lose weight using tyramine-containing supplements or foods on the basis of this finding: it could be dangerous. Individuals concerned about weight management should consult a physician for a healthy, sustainable approach. The obesity-cancer connection in this article is presented as a framework based on the general scientific literature; a direct link between pTOS and cancer prevention has not been demonstrated. All data have been verified against the original Nature Metabolism publication by Long, Leinwand et al., dated 19 March 2026, and institutional statements from Stanford / the University of Colorado Boulder.